{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:59:02Z","timestamp":1769223542478,"version":"3.49.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The efficacy and safety of nilotinib in pediatric patients with imatinib\/dasatinib resistant\/intolerant (R\/I) or newly diagnosed (ND) Philadelphia chromosome\u2013positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase 2, open-label DIALOG study. In this final analysis, long-term efficacy and safety are presented for patients who completed 66 cycles (of 28\u00a0days) of treatment with nilotinib (230\u00a0mg\/m2 twice daily) or discontinued early. Overall, 59 patients were enrolled and 58 were treated (R\/I, n\u00a0= 33; ND, n\u00a0= 25; median time on treatment: 60.5 and 51.9\u00a0months, respectively). In the R\/I cohort, the cumulative major molecular response (MMR; BCR::ABL1 international scale [IS] \u2264 0.1%) rate was 60.6%, and no patients had a confirmed loss of MMR. Among ND patients, the best overall MMR rate was 76.0%; 3 patients had a confirmed loss of MMR. The cumulative molecular response MR4 (BCR::ABL1IS \u2264 0.01%) and MR4.5 (BCR::ABL1IS \u2264 0.0032%) rates by 66 cycles were 27.3% and 12.1% in the R\/I cohort, and 56.0% and 44.0% in the ND cohort, respectively. The safety profile of nilotinib was consistent with those of earlier reports. No on-treatment deaths occurred. These long-term (up to \u223c5 years) data support the efficacy and safety of nilotinib in pediatric patients with Ph+ CML-CP. This trial was registered at www.clinicaltrials.gov.uk as #NCT01844765.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010122","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T16:34:28Z","timestamp":1695400468000},"page":"7279-7289","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-054X","authenticated-orcid":false,"given":"Nobuko","family":"Hijiya","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology\/Stem Cell Transplantation, Columbia University Irving Medical Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":false,"given":"Alexey","family":"Maschan","sequence":"additional","affiliation":[{"name":"2Dmitrii Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-3893","authenticated-orcid":false,"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[{"name":"3Pediatria, Fondazione IRCSS San Gerardo dei Tintori, Universit\u00e1 di Milano-Bicocca, Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-3222","authenticated-orcid":false,"given":"Hiroyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Keio University School of Medicine, Shinjuku-ku, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Dufour","sequence":"additional","affiliation":[{"name":"5Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Seoul National University College of Medicine, Seoul, South Korea"},{"name":"8Seoul National University Cancer Research Institute, Seoul, South Korea"},{"name":"9Seoul National University Children's Hospital, Seoul, South Korea"},{"name":"10Wide River Institute of Immunology, Hongcheon-gun, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Guinipero","sequence":"additional","affiliation":[{"name":"11Nationwide Children's Hospital, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Karakas","sequence":"additional","affiliation":[{"name":"12Pediatric Hematology\/Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-8862","authenticated-orcid":false,"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[{"name":"13Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Hospital Ni\u00f1o Jes\u00fas, Madrid, Spain"},{"name":"14Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Ducassou","sequence":"additional","affiliation":[{"name":"15Groupe Hospitalier Pellegrin-H\u00f4pital des Enfants, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Hee","family":"Yoo","sequence":"additional","affiliation":[{"name":"16Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"14Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"17Department of Pediatric Oncology\/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[{"name":"18Unit\u00e9 d'Onco-H\u00e9matologie P\u00e9diatrique, Centre d'Investigation Clinique (CIC) 1402 INSERM, Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briana C.","family":"Patterson","sequence":"additional","affiliation":[{"name":"19Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-1661","authenticated-orcid":false,"given":"Jill","family":"Samis","sequence":"additional","affiliation":[{"name":"20Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"21Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-388X","authenticated-orcid":false,"given":"Ksenia","family":"Titorenko","sequence":"additional","affiliation":[{"name":"22Novartis Pharmaceuticals Corporations, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Li","sequence":"additional","affiliation":[{"name":"21Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-3482","authenticated-orcid":false,"given":"Darintr","family":"Sosothikul","sequence":"additional","affiliation":[{"name":"23Intergrative and Innovative Hematology\/Oncology Research Unit, Division of Hematology\/Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"issue":"10","key":"2023121116231650600_bib1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and treatment of chronic myeloid leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"2023121116231650600_bib2","doi-asserted-by":"crossref","first-page":"e27827","DOI":"10.1002\/pbc.27827","article-title":"Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children's Oncology Group CML Working Group","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2023121116231650600_bib3","unstructured":"European Medicines Agency\n          . Imatinib summary of opinion. 2013. Accessed 14 March 2023. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-imatinib-accord_en.pdf."},{"key":"2023121116231650600_bib4","article-title":"Gleevec (imatinib). Prescribing information","year":"2022","journal-title":"Novartis Pharmacueticals"},{"key":"2023121116231650600_bib5","article-title":"FDA Approves Dasatinib for Pediatric Patients With CML","year":"2017","journal-title":"FDA"},{"key":"2023121116231650600_bib6","article-title":"European Commission Approves Expanded Indication for Sprycel (Dasatinib) to Include Treatment of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase","year":"2018","journal-title":"Bristol Myers Squibb"},{"key":"2023121116231650600_bib7","article-title":"FDA Approves Nilotinib for Pediatric Patients With Newly Diagnosed or Resistant\/Intolerant Ph+ CML in Chronic Phase","year":"2018","journal-title":"FDA"},{"key":"2023121116231650600_bib8","article-title":"Novartis Drug Tasigna\u00ae (Nilotinib) Secures EU Approval for First and Second-Line Treatment of Ph+ CML-CP in Children","year":"2017","journal-title":"Novartis"},{"issue":"suppl 1","key":"2023121116231650600_bib9","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood-2021-145709","article-title":"A phase I\/II study of bosutinib in pediatric patients with resistant\/intolerant or newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children\u2019s Oncology Group Consortium) AAML1921: results from the phase I trial in resistant\/intolerant patients","volume":"138","author":"Pennesi","year":"2021","journal-title":"Blood"},{"key":"2023121116231650600_bib10","unstructured":"Safety and efficacy of ponatinib for treatment of pediatric recurrent or refractory leukemias, lymphomas or solid tumors. ClinicalTrials.gov identifier: NCT03934372. Updated 27 July 2023. Accessed 14 March 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03934372."},{"key":"2023121116231650600_bib11","unstructured":"Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia. ClinicalTrials.gov identifier: NCT04925479. Updated 28 July 2023. Accessed 14 March 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04925479."},{"issue":"suppl 1","key":"2023121116231650600_bib12","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2021-151198","article-title":"Trial in progress: a multicenter, open-label, phase Ib\/II study to determine the dose and safety of asciminib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with \u22651 prior tyrosine kinase inhibitor","volume":"138","author":"Hijiya","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2023121116231650600_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"2023121116231650600_bib14","article-title":"Tasigna (nilotinib). Prescribing information","year":"2021","journal-title":"Novartis"},{"issue":"7","key":"2023121116231650600_bib15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"issue":"20","key":"2023121116231650600_bib16","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023121116231650600_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J\u00a0Pediatr"},{"issue":"18","key":"2023121116231650600_bib18","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023121116231650600_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"S1","key":"2023121116231650600_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.HS9.0000559876.36369.09","article-title":"PF416 growth rate and endocrine effects of dasatinib therapy observed in a retrospective analysis of a phase 2 clinical trial for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"3","author":"Patterson","year":"2019","journal-title":"HemaSphere"},{"issue":"23","key":"2023121116231650600_bib21","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.2019000069","article-title":"Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"134","author":"Hijiya","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023121116231650600_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.HS9.0000559860.13498.8e","article-title":"PF412 a phase 2 study of nilotinib (NIL) in pediatric patients (pts) with Philadelphia chromosome\u2013positive chronic myeloid leukemia (CML): safety update after 36 cycles of treatment","volume":"3","author":"Hijiya","year":"2019","journal-title":"HemaSphere"},{"issue":"14","key":"2023121116231650600_bib23","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/bloodadvances.2020003759","article-title":"A\u00a0phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety","volume":"5","author":"Hijiya","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2023121116231650600_bib24","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","article-title":"Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia","volume":"26","author":"Hijiya","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023121116231650600_bib25","unstructured":"Study to allow access to nilotinib for patients who are on nilotinib treatment in a Novartis-sponsored study. ClinicalTrials.gov identifier: NCT01735955. Updated 8 August 2023. Accessed 14 March 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01735955."},{"issue":"4","key":"2023121116231650600_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"35","key":"2023121116231650600_bib27","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"235","key":"2023121116231650600_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/adc.44.235.291","article-title":"Variations in pattern of pubertal changes in girls","volume":"44","author":"Marshall","year":"1969","journal-title":"Arch Dis Child"},{"issue":"239","key":"2023121116231650600_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/adc.45.239.13","article-title":"Variations in the pattern of pubertal changes in boys","volume":"45","author":"Marshall","year":"1970","journal-title":"Arch Dis Child"},{"issue":"5","key":"2023121116231650600_bib30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2023121116231650600_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience","volume":"170","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"issue":"13","key":"2023121116231650600_bib32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023121116231650600_bib33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7279\/2176260\/blooda_adv-2023-010122-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7279\/2176260\/blooda_adv-2023-010122-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T16:45:01Z","timestamp":1702313101000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/23\/7279\/497976\/The-long-term-efficacy-and-safety-of-nilotinib-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010122","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}